A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies

The chemokine receptor CXCR4 is highly expressed and associated with poor prognosis in multiple malignancies. Upon engagement by its ligand, CXCL12, CXCR4 triggers intracellular signaling pathways that control trafficking of cells to tissues where the ligand is expressed, such as the bone marrow (BM...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Liu, Shu-Hui, Gu, Yin, Pascual, Bernadette, Yan, Zhengming, Hallin, Max, Zhang, Cathy, Fan, Conglin, Wang, Wenlian, Lam, Justine, Spilker, Mary E., Yafawi, Rolla, Blasi, Eileen, Simmons, Brett, Huser, Nanni, Ho, Wei-Hsien, Lindquist, Kevin, Tran, Thomas-Toan, Kudaravalli, Jyothirmayee, Ma, Jing-Tyan, Jimenez, Gretchen, Barman, Ishita, Brown, Colleen, Chin, Sherman Michael, Costa, Maria J., Shelton, David, Smeal, Tod, Fantin, Valeria R., Pernasetti, Flavia
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2017
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728311/
https://ncbi.nlm.nih.gov/pubmed/29296751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003921
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares